36
Participants
Start Date
May 23, 2023
Primary Completion Date
December 10, 2025
Study Completion Date
December 31, 2025
Low-dose STP0404 (Pirmitegravir)
Once daily, oral capsule taken after breakfast
Medium-dose STP0404 (Pirmitegravir)
Once daily, oral capsule taken after breakfast
High-dose STP0404 (Pirmitegravir)
Once daily, oral capsule taken after breakfast
Placebo
Matching placebo capsule, taken orally once daily after breakfast
RECRUITING
Atrium Health Wake Forest Baptist Medical Center - PPDS, Winston-Salem
RECRUITING
Orlando Immunology Center, Orlando
RECRUITING
Midway Immunology and Research Center, Ft. Pierce
RECRUITING
Be Well Medical Center, Berkley
COMPLETED
North Texas Infectious Diseases Consultants, P.A., Dallas
RECRUITING
St Hope Foundation, Inc, Bellaire
RECRUITING
Kaiser Permenente Los Angeles Medical Center, Los Angeles
RECRUITING
Ruane Clinical Research, Inc., Los Angeles
RECRUITING
Schiff Center for Liver Diseases/University of Miami, Miami
RECRUITING
USF Health South Tampa Center for Advanced Healthcare, Tampa
RECRUITING
Saint Michael's Medical Center, Newark
RECRUITING
South Jersey Infectious Disease, Somers Point
RECRUITING
North Shore University Hospital, Manhasset
ST Pharm Co., Ltd.
INDUSTRY